TREA

USE OF FAS LIGAND TO SUPPRESS ARTHRITIS

Follow

Information

  • Research Project
  • 6294448
  • ApplicationId
    6294448
  • Core Project Number
    R43AI047618
  • Full Project Number
    1R43AI047618-01A1
  • Serial Number
    47618
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/1/2001 - 23 years ago
  • Project End Date
    12/31/2001 - 23 years ago
  • Program Officer Name
    GRETZ, ELIZABETH
  • Budget Start Date
    7/1/2001 - 23 years ago
  • Budget End Date
    12/31/2001 - 23 years ago
  • Fiscal Year
    2001
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    6/22/2001 - 23 years ago
Organizations
Information

USE OF FAS LIGAND TO SUPPRESS ARTHRITIS

DESCRIPTION: Preliminary reports by several groups have demonstrated the potential for Fas ligand-based therapy to prevent transplant rejection, to treat autoimmune disease, to induce immunological tolerance and to treat cancer. The "Use of Fas Ligand to Suppress T-lymphocyte mediated Immune Responses" is protected by U.S. Patent No. 5,759,536, Donald Bellgrau and Richard C. Duke, Inventors. CERES Pharmaceuticals has licensed this Technology from the University of Colorado. The overall goal of this Phase I SBIR application is to develop and test in a well-established mouse model of arthritis, commercially-useful recombinant adenoviral gene therapy vectors encoding mutated versions of Fas ligand with enhanced therapeutic potential. These vectors and strategies for their production and application to treat human rheumatoid arthritis (U.S. Patents Pending) will be licensed to Pharmaceutical and/or Biotechnology companies for use in filing Investigational New Drug (IND) Applications with the FDA in anticipation of phase I clinical trails in humans. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100010
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:100010\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    GLOBEIMMUNE, INC.
  • Organization Department
  • Organization DUNS
    130074495
  • Organization City
    LOUISVILLE
  • Organization State
    CO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    80027
  • Organization District
    UNITED STATES